FDA Fast Tracks Cocrystal’s Norovirus Antiviral CDI-988 — Cocrystal Pharma, Inc.

Event summary

Cocrystal Pharma’s CDI-988, an oral antiviral for norovirus treatment and prevention, received FDA Fast Track designation on April 2, 2026.
CDI-988 is the first oral antiviral candidate targeting norovirus infection, designed to inhibit a highly conserved region of viral proteases.
A Phase 1b clinical trial at Emory University School of Medicine is underway to evaluate CDI-988’s efficacy in preventing and treating norovirus.
Norovirus causes approximately 685 million global cases annually, with an estimated $60 billion economic impact.

The big picture

Cocrystal Pharma’s FDA Fast Track designation for CDI-988 underscores the urgent need for effective norovirus treatments. The company’s structure-based drug discovery platform aims to create broad-spectrum antivirals, addressing a market with substantial economic and health burdens. This development aligns with broader industry trends toward accelerated regulatory pathways for critical infectious disease therapies.

What we're watching

Regulatory Dynamics: How the FDA Fast Track designation will accelerate CDI-988’s development timeline and regulatory review process.
Clinical Trial Progress: Whether the Phase 1b trial at Emory University School of Medicine will yield positive results, validating CDI-988’s potential as a norovirus treatment.
Market Opportunity: The pace at which Cocrystal can capitalize on the unmet medical need for norovirus treatments, given the disease’s significant global impact.